|By PR Newswire||
|April 2, 2014 07:59 PM EDT||
DUBLIN, April 3, 2014 /PRNewswire/ --
Research and Markets (http://www.researchandmarkets.com/research/fz82h5/biomarkers) has announced the addition of the "Biomarkers: Discovery Techniques and Applications - A Global Market Overview" report to their offering.
(Logo: http://photos.prnewswire.com/prnh/20130307/600769 )
The potential offered by biomarkers in shaping the outcomes of clinical trials, identifying new drug targets and developing diagnostic assays for detecting diseases early is immense, which has ensued in a large number of scientific publications coming out over the past two decades. Biomarker research encompasses widespread fields of discipline, which comprise drug discovery, toxicity, clinical markers of efficacy and therapeutic indicators, development of diagnostic assays and environmental pollutant exposure. The fields of epidemiology and toxicology have also made use of biomarkers in indicating exposure to a range of environmental substances. In such instances, the biomarker could be the substance itself, such as asbestos particles or nicotine-derived nitrosamine ketone (NNK) from tobacco, or a variation of the external substance processed by the body, such as a metabolite. Using biomarkers in species, such as aquatic animals and invertebrates can be helpful in determining levels and ranges of environmental pollutants.
Personalized medicine constitutes another facet that has been in an ever increasing mode, wherein genomic data are utilized for classifying subsets of patients that would respond to a specific line of therapy. The progression of biomarker research in ascertaining the basics of personalized medicine implies that the prospects of jointly developing drugs and biomarkers would be associated with identifying that section of the population that would garner the maximum benefit from that drug treatment. Developing such biomarkers requires expending considerable efforts and resources, which would enable in expanding the tasks accomplished by biomarkers in disease screening as surrogate endpoints and diagnostic indices.
Biomarker discovery techniques analyzed in this report include Bioimaging, Bioinformatics and Omics Technologies. On a broader geographic level, these technologies further drilled down to Bioimaging - Computed Tomography (CT), Magnetic Resonence Imaging (MRI), Ultrasound and Other; and Omics Technologies - Genomics, Metabolomics, Proteomics and Other. The study also explores the global market for therapeutic areas of biomarkers comprising Cardiology, Neurology, Oncology and Other.
Key Topics Covered:
PART A: GLOBAL MARKET PERSPECTIVE
2. KEY MARKET TRENDS
3. KEY MAJOR PLAYERS
4. KEY BUSINESS TRENDS
5. GLOBAL MARKET OVERVIEW
PART B: REGIONAL MARKET PERSPECTIVE
REGIONAL MARKET OVERVIEW
1. THE UNITED STATES
4. REST OF WORLD
PART C: GUIDE TO THE INDUSTRY
1. NORTH AMERICA
4. REST OF WORLD
PART D: ANNEXURE
1. RESEARCH METHODOLOGY
- ACE Biosciences A/S
- Abbott Laboratories, Inc.
- Affibody AB
- Affymetrix, Inc.
- Agendia N.V.
- Agilent Technologies, Inc.
- Altheadx, Inc.
- Amgen, Inc.
- Analytical Biological Services Inc.
- Astrazeneca Plc
- BG Medicine, Inc.
- Banyan Biomarkers Inc.
- Bayer AG
- Beckman Coulter, Inc.
- Becton, Dickinson and Company
- Bio-Rad Laboratories, Inc.
- Biocartis SA
- Biomérieux SA
- Boehringer Ingelheim GmbH
- Bristol-Myers Squibb Company
- Bruker Corporation
- Celera Corporation
- Charles River Laboratories International, Inc.
- Clarient, Inc.
- Compugen Ltd.
- Decode Genetics
- Dr. Reddy's Laboratories Limited
- EMD Millipore Corporation
- Epigenomics AG
- F. Hoffmann-La Roche Ltd.
- GE Healthcare Ltd.
- Genedata AG
- Glaxosmithkline, Plc
- Johnson & Johnson
- Merck & Co., Inc.
- Nordion Inc.
- Novartis AG
- Perkinelmer Inc.
- Pfizer, Inc.
- Pharmaceutical Product Development, LLC.
- Philips Healthcare
- Ranbaxy Laboratories Limited
- Roche Diagnostics Corporation
- Rosetta Genomics Ltd.
- Shimadzu Scientific Instruments, Inc
- Siemens Healthcare
- Siemens Healthcare Diagnostics, Inc.
- Sigma-Aldrich Corporation
- Takeda Pharmaceutical Company Limited
- Thermo Fisher Scientific Inc
- UCB S.A.
For more information visit http://www.researchandmarkets.com/research/fz82h5/biomarker
Media Contact: Laura Wood , +353-1-481-1716, [email protected]
SOURCE Research and Markets
Aug. 28, 2016 07:30 AM EDT Reads: 758
Aug. 28, 2016 07:00 AM EDT Reads: 2,386
Aug. 28, 2016 03:30 AM EDT Reads: 2,351
Aug. 28, 2016 02:00 AM EDT Reads: 1,769
Aug. 28, 2016 01:45 AM EDT Reads: 2,155
Aug. 28, 2016 01:30 AM EDT Reads: 2,091
Aug. 28, 2016 01:00 AM EDT Reads: 2,966
Aug. 28, 2016 12:15 AM EDT Reads: 1,832
Aug. 27, 2016 11:00 PM EDT Reads: 4,004
Aug. 27, 2016 08:45 PM EDT Reads: 2,357
Aug. 27, 2016 08:45 PM EDT Reads: 1,781
Aug. 27, 2016 06:00 PM EDT Reads: 3,106
Aug. 27, 2016 06:00 PM EDT Reads: 742
Aug. 27, 2016 05:15 PM EDT Reads: 1,585
Aug. 27, 2016 05:00 PM EDT Reads: 1,891